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The safety and tolerability of indacaterol, a novel once-daily b2-agonist bronchodilator
with a fast onset of action, were assessed in 156 asthma patients in a multicentre,
randomized, double-blind, placebo-controlled study. Patients received indacaterol 200,
400 or 600 mg or placebo once daily for 28 days. Adverse events (AEs), laboratory
assessments, vital signs, electrocardiograms, spirometry and physical examinations were
monitored. Indacaterol pharmacokinetics were assessed.
There was no evidence of dose-related increases in AE incidence or clinically significant
hypokalaemia or hyperglycaemia in indacaterol-treated patients. Mean pulse rate changes
were minor in any group, with maximum 1-h post-dose changes from baseline of 3.7,
3.3 and 2.2 bpm for indacaterol 200, 400 and 600 mg, respectively, and 2.9 bpm for
placebo. Mean QTc interval was similar between groups; change from baseline 460ms
occurred in only two patients. Mean FEV1 increased after the first indacaterol dose;
baseline-adjusted pre-dose (trough) values remained X166mL higher than placebo at all
subsequent visits, supporting a 24-h bronchodilator effect. Pre-dose (but not post-dose)
serum indacaterol concentrations indicated a slight trend for accumulation.Elsevier Ltd. All rights reserved.
65 5264; fax: +1 95 465 5364.
.com (A.G. Chuchalin).
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A.G. Chuchalin et al.2066Once-daily indacaterol 200–600 mg has a favourable therapeutic index. It is well tolerated,
and is not associated with any adverse cardiac or metabolic effects, while providing
effective 24-h bronchodilation.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Inhaled b2-agonists are the most effective bronchodilators
for the prevention and relief of bronchoconstriction asso-
ciated with asthma, and therefore have an important role in
managing asthma symptoms.1–3 Long-acting b2-agonists,
such as salmeterol and formoterol, have 12-h durations of
action, and their recommended use is in combination with
inhaled corticosteroids (ICS) in patients with moderate or
severe persistent asthma.1
Selective b2-agonists were developed to minimize the b1-
mediated chronotropic effects that were associated with
the non-selective agents such as isoprenaline. b2-receptors
are also present in myocardial tissue, and the occurrence of
tachycardia and palpitations has been associated with the
use of selective b2-agonists, especially at higher doses.
Other dose-limiting b2-mediated side effects include skele-
tal muscle tremor, hyperglycaemia and hypokalaemia.4
Thus, an important property of a new b2-agonist is to
provide effective bronchodilation at a dose that is not
associated with these side effects and to have a wide safety
margin with higher doses.
Indacaterol is a novel once-a-day and fast-acting b2-
agonist in development for the treatment of asthma and
chronic obstructive pulmonary disease (COPD). Preclinical
data suggest that, for a given degree of bronchodilator
activity, indacaterol has a greater cardiovascular safety
margin than formoterol or salmeterol.5 In-vivo guinea pig
studies with indacaterol have demonstrated a sustained
bronchodilator and bronchoprotective effect, and a rapid
onset of action (comparable to salbutamol and formoterol).5
The aim of the current study was to assess the safety and
tolerability of indacaterol 200, 400 and 600 mg compared
with placebo, dosed once daily over 28 days in patients with
asthma. The 200 mg dose was selected as a potentially
therapeutic dose based on the results of a previous Phase I
study.6 Particular attention was paid to the predictable
pharmacological effects of a b2-agonist on serum potassium,
blood glucose, heart rate, blood pressure, QTc, and
occurrence of tremor, headache and nervousness.Methods
Design
This was a Phase II, multicentre, randomized, double-blind,
placebo-controlled, parallel-group study in adolescents and
adults with asthma. Patients enrolled in the study entered a
14-day run-in phase. Study treatment was then given for 28
days, with follow-up for a further 7 days to assess asthma
stability and adverse events after treatment cessation.
Patients attended the study centre on five occasions: at the
start of the run-in phase; at the start of the double-blindtreatment phase, after 14 and 28 days of treatment, and at
the 7-day follow-up.
All patients gave written informed consent prior to the
start of the study. The study was conducted according to
Good Clinical Practice guidelines and in accordance with the
Declaration of Helsinki.7
Inclusion and exclusion criteria
Male and female patients aged 13–75 years with asthma
diagnosed according to GINA 2002 guidelines8 were enrolled
if they were receiving daily treatment with an inhaled b2-
agonist with or without inhaled corticosteroids at a dose of
up to 1600 mg beclometasone dipropionate (or equivalent),
in a regimen that had remained stable for at least the past
month, and their forced expiratory volume in 1 s (FEV1) was
at least 60% of the predicted normal value,9 with at least
12% reversibility within 30min after inhalation of 400 mg
(2 2 inhalations) of salbutamol (either demonstrated at
screening or documented within the prior 6 months).
Pregnant or breastfeeding women or women of childbearing
potential not using reliable contraception were excluded.
Patients with COPD, current or recent smokers or those with a
smoking history of 410 pack-years were excluded. Patients
were also excluded if they had been hospitalized or received
emergency treatment for asthma in the last 3 months, or if
they had a respiratory tract infection in the last month, or
concomitant pulmonary disease. Other exclusion criteria
included abnormal blood test or electrocardiogram (ECG)
results, and any clinically significant condition that could
compromise patient safety or conduct of the study.
Study treatment
Patients were randomized using a validated automated
system in the ratio 1:1:1:1 to receive indacaterol 200, 400 or
600 mg or placebo once daily by inhalation from hydrofluor-
oalkane (HFA) metered dose inhalers (pMDIs). To ensure
blinding, indacaterol and placebo devices were identical in
appearance.
Inhaled salbutamol was permitted as rescue medication.
Patients who had been using long-acting b2-agonists prior to
the study were instructed to use salbutamol on a regular
basis for the duration of the run-in phase and as needed
during the randomized treatment phase. The steroid
component of combination (inhaled corticosteroid and b2-
agonist) therapy was replaced with the equivalent mono-
therapy inhaled corticosteroid. Those patients on ‘‘mono-
therapy’’ inhaled corticosteroid continued on the pre-study
steroid regimen. Patients could use nasal corticosteroids,
antihistamines, cromones, ketotifen and leukotriene an-
tagonists, provided that treatment had been stable for 1
month prior to the study. Desensitization therapy for rhinitis
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Indacaterol safety and tolerability in asthma 2067was permitted, provided that treatment had been stable for
the previous 3 months.
Assessments
Safety was assessed, as the primary objective, by recording
all adverse events, regular monitoring of haematology,
blood chemistry and urinalysis, vital signs, electrocardio-
grams (ECGs), spirometry, and physical examinations.
On Days 1, 14 and 28, pre-dose and 60min post-dose (the
estimated time of maximum systemic exposure [Cmax] to
indacaterol post inhalation), assessments were made in the
following order: ECG, diastolic and systolic blood pressure,
and blood samples (non-fasting) for laboratory evaluation.
ECG and blood pressure were assessed after the patient had
rested in the sitting position for at least 5min. Electro-
cardiographic events of rate, rhythm, conduction activation
and repolarization were derived from standardized 12-lead
ECGs. Both Bazett’s and Fridericia’s formulae were used to
calculate the QTc interval. Blood samples were analysed at a
central laboratory (BARC [Bio Analytical Research Corpora-
tion], Ghent, Belgium) and ECGs were reviewed by a single
cardiologist (at ERT [eResearch Technology], Peterborough,
UK) for purposes of standardization.
Spirometry was performed before and 30min after dosing
on Days 1, 14 and 28. At the Days 14 and 28 visits, patients
were asked to estimate their mean daily use of salbutamol
over the past 14 days.
Pharmacokinetic assessments
Systemic exposure to indacaterol was assessed, with venous
blood samples taken pre-dose and 60min post-dose (at the
same time as those for blood chemistry/haematology) on
Days 1, 14 and 28 of treatment. The aims of the
pharmacokinetic evaluations were to investigate the possi-
ble dose relationship and whether serum accumulation of
indacaterol would occur.
Blood (3mL) was drawn into a plain polypropylene tube,
and a serum sample was prepared and stored at 20 1C
before analysis by validated liquid chromatography/tandem
mass spectrometry (LC/MS/MS), with a lower limit of
quantification for indacaterol of 0.05 ng/mL. Intra-assay
accuracy was accepted when calibrations were within720%
of nominal values and reproducibility of the method was
within 715% for a set of six quality control samples.
Statistical methods
As this study was a hypothesis-generating rather than
hypothesis-testing study, no formal sample size calculation
was performed. To generate sufficient safety and toler-
ability data to justify the commencement of large-scale
studies with indacaterol, approximately 100 patients were
to be exposed to indacaterol for 28 days. Therefore,
assuming a 10% dropout rate and taking into account that
25% of patients would be randomized to placebo, 148
patients were to be enrolled. Safety variables were
summarized or analysed for the safety population, which
consisted of all randomized patients who received at least
one dose of study medication. Adverse events were definedas those that started or worsened after initiation of study
medication. Serum potassium, blood glucose, pulse rate,
diastolic and systolic blood pressure, QTc interval and FEV1
were analysed using an analysis of covariance (ANCOVA)
model with centre, treatment and baseline value as
covariates. All analyses were performed using SAS/STAT
software (Version 8 of the SAS System for Unix, SAS Institute
Inc., Cary, NC, USA).
For the pharmacokinetic data, separate statistical ana-
lyses were conducted for each indacaterol dose as well as
for the pre-dose and post-dose measurements. Patients
were excluded from the analysis if Day 14 or 28 data were
missing because of study discontinuation, or if there was no
sample or insufficient sample for analysis. Data were
analysed using a mixed linear model in which the day was
a fixed effect and the subject was a random effect. This was
stratified by dose and time (pre-dose or post-dose); the
difference in arithmetic means and corresponding 90%
confidence intervals (CIs) were determined for each dose
and time point. The concentration–dose relationship was
investigated with a linear regression analysis.
Results
Patients
Patients were recruited at 18 centres in four countries
(Denmark [five centres], Germany [four], the Netherlands
[six] and Russia [three]). Of 191 patients screened, 156
patients were randomized between February and July 2003.
All randomized patients received at least one dose of study
drug, although five patients did not complete the study
(Fig. 1). Demographic and baseline characteristics were well
balanced between the treatment groups (Table 1).
Adverse events
Most adverse events were mild, with only one described as
severe—a tendon rupture in a patient receiving indacaterol
400 mg. As expected in this population, respiratory-related
disorders were the most frequent adverse events, followed
by nervous system disorders and infections (Table 2). There
was no indication of a dose-related increase in the incidence
of adverse events in any body system, although in general
patients on indacaterol had slightly higher incidences of
respiratory and nervous system disorders than those on
placebo. The most frequent adverse event was nasophar-
yngitis (15% in the indacaterol 200 mg group). Headache was
reported in three (7.7%), five (12.8%), zero, and two (5.4%)
patients in the placebo and indacaterol 200, 400 and 600 mg
groups, respectively. Tremor was reported by two (5.4%)
patients in the indacaterol 600 mg group, and there were no
reports of nervousness. Cough occurred at a higher
frequency in patients receiving indacaterol compared with
placebo, experienced by one (2.6%), four (10.3%), seven
(17.1%) and three (8.1%) patients in the placebo and
indacaterol 200, 400 and 600 mg groups, respectively. The
majority of coughing events were considered as being of
mild severity.
There were no serious adverse events in any patients
receiving indacaterol. One placebo recipient was hospitalized
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Figure 1 Flow of patients during the study.
A.G. Chuchalin et al.2068because of hypoglycaemia. One patient discontinued be-
cause of cough (indacaterol 400 mg) and two because of
asthma exacerbations (one placebo and one indacaterol
600 mg); these events were of moderate severity and
not considered to be related to the study drug by the
investigator.Laboratory values and biochemistry
There was no evidence of any drug or dose-related effects
on the standard haematological tests in any treatment
group.
A reduction in serum potassium is considered to be one of
the dose-limiting b2-mediated side effects. No indacaterol
dose was associated with statistically significant reductions
in mean serum potassium versus placebo at any time point
(Fig. 2a). The only statistically significant between-treat-
ment comparison was an increase of 0.21mmol/L on day 1
post-dose between the indacaterol 200 and 400 mg
groups (p ¼ 0.01). At the same time point, an increase of
0.15mmol/L was observed between indacaterol 200 and
600 mg groups (p ¼ 0.05, regarded as not clinically signifi-
cant). No further significant comparisons between treat-
ment groups in potassium levels were noted, suggesting that
the isolated statistically significant Day 1 post-dose differ-
ences were a random finding. There were no clinically
significant changes in mean serum potassium levels and no
evidence of drug-related hypokalaemia. Individual serum
potassium levels remained above the lower limit of normal
(3.5mmol/L), with the exception of post-dose measure-
ments in the indacaterol 400 mg group on Day 1 (one patient,
3.3mmol/L), Day 14 (one patient, 3.4mmol/L) and Day 28
(two patients, both 3.3mmol/L).
An increase in blood glucose is considered to be one of the
dose-limiting b2-mediated side effects. There were nostatistically or clinically significant differences in mean
blood glucose values between the treatment groups
(Fig. 2b), and no evidence of drug- or dose-related hyper-
glycaemia. Individual blood glucose levels remained below
the upper limit of normal (7.77mmol/L), except for three
patients (four episodes) in the placebo group (maximum of
8.82mmol/L, post-dose on Day 1), one patient (one episode)
in the indacaterol 200 mg group (8.99mmol/L, post-dose on
Day 1), three patients (11 episodes) in the indacaterol
400 mg group (maximum of 10.8mmol/L, post-dose on Day
1), and one patient (four episodes) in the indacaterol 600 mg
group (maximum of 10.2mmol/L, pre-dose on Day 14).
One patient in the placebo group was withdrawn at the
request of the study sponsor because of elevated creatinine
kinase values that were elevated prior to dosing.
There was no evidence of either a drug- or dose-related
effect in any of the other biochemical variables measured.Vital signs
Mean pulse rate and blood pressure changes were minimal,
with no statistically significant differences between treat-
ment groups (although for diastolic blood pressure post-dose
on Day 1 the difference between indacaterol 400 and 200 mg
was p ¼ 0.05, regarded as not clinically significant; Table 3).
Overall, 16 patients had isolated pre- or post-dose readings
of pulse rates 490 bpm (three, four, four and five, in the
placebo and indacaterol 200, 400 and 600 mg groups,
respectively). The maximum individual post-baseline pulse
rates observed in each treatment group were: placebo,
100 bpm; indacaterol 200 mg, 107 bpm; 400 mg, 102 bpm;
600 mg, 97 bpm. The greatest individual increase from
baseline in the indacaterol 600 mg group was 25 bpm (from
71 to 96 bpm), compared with an increase of 31 bpm seen in
the placebo group (from 60 to 91 bpm).
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Table 1 Baseline demographics and disease characteristics (all randomized patients).
Placebo Indacaterol
200 mg 400 mg 600 mg
Median age (yr) (range) 45.0 (20–67) 50.0 (22–67) 49.0 (18–73) 52.0 (20–71)
Sex, n (%)
Male 20 (51.3) 17 (43.6) 20 (48.8) 19 (51.4)
Female 19 (48.7) 22 (56.4) 21 (51.2) 18 (48.6)
Race, n (%)
Caucasian 38 (97.4) 39 (100) 40 (97.6) 37 (100)
Other 1 (2.6) 0 1 (2.4) 0
Median BMI (kg/m2) (range) 26.8 (18.1–37.7) 26.8 (20.1–41.1) 25.5 (19.5–37.6) 25.4 (19.1–33.7)
Smoking history, n (%)
Never smoked 33 (84.6) 29 (74.4) 35 (85.4) 28 (75.7)
Ex-smoker 6 (15.4) 10 (25.6) 6 (14.6) 9 (24.3)
Median asthma duration (yr) (range) 18.0 (3–62) 13.0 (3–41) 15.0 (1–48) 16.0 (1–48)
FEV1 pre-salbutamol (L)
Mean (SD) 2.6 (0.74) 2.6 (0.84) 2.6 (0.79) 2.6 (0.65)
FEV1 % predicted (%)
Mean (SD) 77.0 (11.68) 81.3 (12.85) 79.0 (13.33) 80.1 (12.25)
FEV1 reversibility (%)
Mean (SD) 19.4 (11.50) 15.4 (6.40) 18.3 (9.32) 17.8 (7.80)
Salbutamol use, n (%)a
None 1 (2.6) 1 (2.6) 0 0
o1 puff/day 11 (28.2) 9 (23.1) 6 (14.6) 4 (10.8)
1–2 puffs/day 7 (17.9) 10 (25.6) 9 (22.0) 15 (40.5)
3–6 puffs/day 16 (41.0) 17 (43.6) 19 (46.3) 13 (35.1)
46 puffs/day 4 (10.3) 2 (5.1) 7 (17.1) 5 (13.5)
Prior/concomitant asthma medications
Long-acting b2-agonist
b 11 (28.2) 13 (33.3) 13 (31.7) 13 (35.1)
Inhaled corticosteroidsc 32 (82.1) 34 (87.2) 39 (95.1) 29 (78.4)
Placebo (n ¼ 39); indacaterol 200 mg (n ¼ 39); 400mg (n ¼ 41); 600 mg (n ¼ 37).
BMI: body mass index; FEV1: forced expiratory volume in 1 s.
aAverage daily use estimated by investigator based on patient information during run-in.
bDiscontinued at the start of the run-in.
cStarted prior to randomization and continued throughout treatment period.
Table 2 Number (%) of patients with adverse events by treatment group (safety population).
Placebo Indacaterol
200 mg 400 mg 600 mg
Total no. of patients studied 39 39 41 37
Total no. with adverse events 13 (33.3) 16 (41.0) 17 (41.5) 15 (40.5)
Primary system organ class
Infections and infestations 4 (10.3) 7 (17.9) 1 (2.4) 1 (2.7)
Respiratory, thoracic and mediastinal disorders 4 (10.3) 7 (17.9) 9 (22.0) 7 (18.9)
Nervous system disorders 3 (7.7) 6 (15.4) 2 (4.9) 4 (10.8)
General disorders and administration site conditions 1 (2.6) 2 (5.1) 3 (7.3) 0
Gastrointestinal disorders 0 1 (2.6) 0 2 (5.4)
Investigations 1 (2.6) 1 (2.6) 0 0
Musculoskeletal and connective tissue disorders 1 (2.6) 1 (2.6) 2 (4.9) 2 (5.4)
Cardiac disorders 0 0 1 (2.4) 1 (2.7)
Immune system disorders 1 (2.6) 0 0 0
Injury, poisoning and procedural complications 0 0 2 (4.9) 1 (2.7)
Metabolism and nutrition disorders 1 (2.6) 0 0 0
Skin and subcutaneous tissue disorders 1 (2.6) 0 0 3 (8.1)
Data are presented as n (%).
Indacaterol safety and tolerability in asthma 2069
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Figure 2 (a) Mean (SD) serum potassium over time. (b) Mean (SD) blood glucose over time. ’: indacaterol 200 mg (n ¼ 39); :
indacaterol 400 mg (n ¼ 41); &: indacaterol 600 mg (n ¼ 37); : placebo (n ¼ 39). *p ¼ 0.01 versus indacaterol 400 mg.
A.G. Chuchalin et al.2070Although a significant proportion of patients had pre- and
post-dose systolic blood pressure values 4140mmHg, there
were no drug-related trends or major differences between
the indacaterol and placebo groups. Similarly, although
some patients had elevated pre- and post-dose diastolic
values, no trends were apparent, and no low values
(o50mmHg) were seen.ECG
There were no differences in mean QTc interval between
any of the treatment groups (Fig. 3) and only one patient
(indacaterol 400 mg) had a notable value (male; 451ms;
Bazett’s formula) during treatment. Notable changes from
baseline in QTc interval (460ms) occurred in one patient in
the indacaterol 200 mg group (both formulae), and one
patient in the 600 mg group (Bazett’s formula only) but did
not exceed the upper limit of normal (430ms for males,
450ms for females; Table 4). Although using Bazett’s
formula resulted in a higher incidence of QTc interval
prolongation between 30 and 60ms compared with placebo,
this was not confirmed with Fridericia’s formula, and there
was no evidence of a dose-related increase in QTc interval
values (Table 4). Twelve patients on indacaterol treatments
had QTc interval increases X30ms from baseline according
to Fridericia’s formula, none of which exceeded the upper
limit of normal. In eight of these cases, the values were not
notable compared with screening values. Of the remainingpatients, three were receiving the lowest dose (200 mg) and
one was receiving indacaterol 400 mg. Overall, no clinically
relevant effect on QTc interval was observed for indacaterol
in the dose range studied.FEV1 and salbutamol use
In the placebo group there was a slight but gradual decline
in mean FEV1 over the course of the study (Fig. 4). In
contrast, mean trough pre-dose FEV1 increased after the
first dose of indacaterol and remained above baseline at all
post-baseline time points, with no evidence of a clinically
relevant reduction in bronchodilator efficacy over time.
Adjusting for baseline FEV1 values, there was a difference of
at least 166mL between placebo and any indacaterol group
in mean trough pre-dose FEV1.
Post-dose FEV1 (measured at 30min) was statistically
superior to placebo (po0.05) with all indacaterol doses on
each assessment day. The difference relative to placebo was
in excess of 220mL for all post-dose FEV1 measurements
apart from on Day 1 for indacaterol 200 mg. Overall, a
decrease in FEV1 of 4200mL from baseline occurred in
approximately half of the placebo group (18 patients; 46%),
compared with five (13%), three (7%) and three (8%) patients
for indacaterol 200, 400 and 600 mg, respectively. None of
these patients treated with indacaterol had cough or other
signs of bronchial irritation associated with the FEV1
decrease.
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Table 3 Cardiovascular assessments (safety population).
Placebo Indacaterol
200 mg 400 mg 600 mg
Mean pulse rate (bpm) (SD)
Pre-dose, Day 1 (baseline) 69.0 (10.49) 70.5 (9.50) 71.3 (11.26) 69.3 (9.25)
Post-dose, Day 1 66.1 (9.39) 66.8 (9.49) 68.1 (9.33) 67.1 (12.35)
Pre-dose, Day 14 69.5 (9.46) 70.7 (11.36) 70.5 (10.46) 70.7 (10.81)
Post-dose, Day 14 66.8 (8.60) 67.5 (8.59) 68.5 (10.34) 68.9 (11.00)
Pre-dose, Day 28 69.8 (11.24) 70.9 (11.62) 71.5 (9.86) 72.6 (12.33)
Post-dose, Day 28 67.3 (7.80) 67.8 (10.95) 68.0 (11.23) 68.9 (10.65)
Mean systolic blood pressure (mmHg) (SD)
Pre-dose, Day 1 (baseline) 129.5 (17.80) 127.5 (15.10) 126.3 (12.22) 126.0 (15.54)
Post-dose, Day 1 128.8 (16.33) 128.3 (13.13) 125.9 (11.87) 126.9 (14.94)
Pre-dose, Day 14 128.1 (14.06) 128.8 (13.53) 125.2 (12.79) 126.7 (14.64)
Post-dose, Day 14 129.4 (16.54) 130.1 (14.28) 126.2 (12.80) 126.6 (15.38)
Pre-dose, Day 28 128.0 (17.15) 129.6 (13.20) 126.3 (12.69) 126.2 (11.67)
Post-dose, Day 28 128.4 (17.10) 130.7 (14.60) 125.8 (12.74) 127.7 (14.11)
Mean diastolic blood pressure (mmHg) (SD)
Pre-dose, Day 1 (baseline) 79.1 (8.85) 79.9 (9.76) 79.7 (7.72) 78.0 (8.32)
Post-dose, Day 1 79.0 (6.76) 80.4 (7.83) 77.8 (8.52) 78.1 (10.52)
Pre-dose, Day 14 78.7 (10.06) 80.9 (8.35) 78.4 (9.44) 79.8 (7.57)
Post-dose, Day 14 79.2 (9.63) 79.7 (8.84) 79.4 (8.55) 77.4 (9.96)
Pre-dose, Day 28 77.2 (11.00) 80.6 (8.11) 80.2 (8.93) 78.8 (7.70)
Post-dose, Day 28 79.1 (10.95) 80.3 (7.92) 79.5 (8.69) 76.7 (8.72)
Placebo (n ¼ 39); indacaterol 200 mg (n ¼ 39); 400mg (n ¼ 41); 600 mg (n ¼ 37).
No statistically significant differences were observed in mean pulse rate, mean systolic or diastolic blood pressure (although for
diastolic blood pressure post-dose on Day 1 the difference between indacaterol 400 and 200mg was p ¼ 0.05, regarded as not clinically
significant).
Figure 3 Mean (SD) QTc intervals (Bazett’s) over time. ’: indacaterol 200 mg (n ¼ 39); : indacaterol 400 mg (n ¼ 41); &:
indacaterol 600 mg (n ¼ 37); : placebo (n ¼ 39).
Indacaterol safety and tolerability in asthma 2071Daily use of salbutamol decreased during the study in all
treatment groups (Table 5). There was evidence for a trend
of decreased use of salbutamol with increasing dose of
indacaterol.Pharmacokinetic assessments
From the indacaterol 200, 400 and 600 mg groups, 39, 41 and
36 patients, respectively, provided evaluative data. Therewas high inter-subject variability in the pre-dose sample
results as trough levels approached the limit of quantifica-
tion of the assay (0.05 ng/mL). Variability within the post-
dose results was acceptable. Mean pre-dose and post-dose
serum concentrations increased with indacaterol dose on all
days (Fig. 5). The differences in pre-dose arithmetic means
(and 90% CIs) between Day 28 and Day 14 were 0.002
(0.007, 0.012), 0.024 (0.002, 0.045) and 0.035 (0.018,
0.052) ng/mL for indacaterol 200, 400 and 600 mg, respec-
tively, indicating a trend for slight accumulation of
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Figure 4 Mean (SD) forced expiratory volume in one second (FEV1) over time.’: indacaterol 200 mg (n ¼ 39); : indacaterol 400 mg
(n ¼ 41); &: indacaterol 600 mg (n ¼ 37); : placebo (n ¼ 39). *po0.05 versus placebo; ypo0.05 versus indacaterol 200 mg;
zpo0.05 versus indacaterol 400 mg.
Table 4 Notable QTc intervals and changes by treatment (safety population).
Placebo Indacaterol
200 mg 400 mg 600 mg
Patients with notable values, n (%)
Bazett’s formula
Male (4450ms) 0 0 1 (2.4) 0
Female (4470ms) 0 0 0 0
Changea o30ms 36 (92.3) 32 (82.1) 34 (82.9) 28 (75.7)
Changea 30–60ms 3 (7.7) 6 (15.4) 7 (17.1) 8 (21.6)
Changea 460ms 0 1 (2.6) 0 1 (2.7)
Fridericia’s formula
Male (4450ms) 0 0 0 0
Female (4470ms) 0 0 0 0
Changea o30ms 36 (92.3) 34 (87.2) 38 (92.7) 33 (89.2)
Changea 30–60ms 3 (7.7) 4 (10.3) 3 (7.3) 4 (10.8)
Changea 460ms 0 1 (2.6) 0 0
Placebo (n ¼ 39), indacaterol 200mg (n ¼ 39), 400 mg (n ¼ 41), 600mg (n ¼ 37).
aChange from baseline to worst (highest) post-baseline value.
Table 5 Daily salbutamol use between visits and by treatment (safety population).
Period Average puffs/day since last visit Placebo Indacaterol
200 mg 400 mg 600 mg
Screening to Day 1 None 1 (2.6) 1 (2.6) 0 0
o3 puffs/day 18 (46.2) 19 (48.7) 15 (36.7) 19 (51.4)
X3 puffs/day 20 (51.3) 19 (48.7) 26 (63.4) 18 (48.6)
Days 1–14 None 6 (15.4) 10 (25.6) 12 (29.3) 16 (43.2)
o3 puffs/day 21 (53.8) 28 (71.8) 23 (56.1) 17 (45.9)
X3 puffs/day 11 (28.2) 1 (2.6) 6 (14.6) 2 (5.4)
Days 14–28 None 5 (12.8) 10 (25.6) 12 (29.3) 18 (48.6)
o3 puffs/day 25 (64.1) 27 (69.2) 24 (58.5) 16 (43.2)
X3 puffs/day 7 (17.9) 2 (5.1) 4 (9.8) 1 (2.7)
Data are presented as n (%). Placebo (n ¼ 39); indacaterol 200mg (n ¼ 39); 400 mg (n ¼ 41); 600mg (n ¼ 37).
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Figure 5 Mean (SD) indacaterol serum concentrations. ’: indacaterol 200 mg (n ¼ 39); : indacaterol 400 mg (n ¼ 41); &:
indacaterol 600 mg (n ¼ 36).
Indacaterol safety and tolerability in asthma 2073indacaterol over time. However, accumulation could not be
concluded from the analysis of the corresponding post-dose
values, where differences between Day 14 and Day 28 were
0.013 (0.038, 0.012), 0.013 (0.035, 0.061) and 0.016
(0.061, 0.028), for indacaterol 200, 400 and 600 mg,
respectively.
Although exposure to indacaterol increased with increasing
dose, the limited sampling strategy did not allow conclusions
regarding dose-proportionality. The linear regression returned
adjusted coefficients of determination (adjusted R2) of 0.26
and 0.29 pre-dose on Days 14 and 28, respectively, and 0.30,
0.39 and 0.33 post-dose on Days 1, 14 and 28, respectively,
indicating that the variability in the data was too high to allow
for assessment of dose-proportionality.Discussion
This was a safety study, the objective of which was to
examine the effect of indacaterol, at doses up to 600 mg, on
key safety variables commonly associated with b2-agonist
use. The results support a favourable safety profile of
indacaterol in patients with asthma. The frequency of
adverse events was low and indacaterol was not associated
with adverse cardiovascular effects at doses of up to 600 mg
once daily for 28 days. These findings confirm and extend
the results of a single-dose, dose-ranging study in patients
with asthma,10 and provide clinical confirmation of the
favourable pre-clinical findings on the cardiovascular safety
profile of indacaterol.5 The reduction of asthma symptoms
associated with bronchospasm during the use of the long-
acting b2-agonists formoterol and salmeterol, when given
twice daily, is well established.1 A selective b2-agonist that
can provide safe and effective 24-h bronchodilation with
once-daily dosing extends the treatment options for many
patients with asthma, as well as potentially contributing to
patient compliance, especially among adolescents and
children.11,12
The very low incidence of predictable pharmacological
side effects such as tremor, headache, nervousness, nausea
and tachycardia, together with negligible effects on QTc
interval, blood glucose and serum potassium, over a wide
range of doses suggests a favourable therapeutic index for
indacaterol. Changes in heart rate, QTc interval and plasmapotassium and glucose levels have been reported in patients
and healthy volunteers receiving the long-acting b2-agonists
salmeterol13–15 and formoterol16–19 at higher doses than
indicated for clinical use. In this study doses of up to 600 mg
once daily for 28 days were not associated with an increase
in side effects.
It might be considered somewhat unusual that there were
no changes in key safety variables for the higher doses of
indacaterol in this study, except for occasional changes in
serum potassium. This may be because doses used were
simply not high enough to have an impact on these safety
variables despite all indacaterol doses achieving clinically
relevant differences in FEV1 of 4200ml versus placebo at
most post-dose time points. In a subsequent study, higher
doses of indacaterol (800 mg) demonstrated effects on serum
potassium and blood glucose; however, these changes were
considered to be not clinically meaningful.20 At a higher
single dose of 1000 mg, indacaterol had a good safety profile
and was not associated with sustained systemic adverse
effects; mean heart rate and QTc interval remained within
normal ranges following administration.21
Hypoxemia due to respiratory insufficiency is a key
problem in asthma, particularly during acute severe
exacerbations, and results in adverse cardiovascular effects,
including prolongation of the QTc interval.22,23 A potential
effect on QTc interval is applicable to all b2-agonists,
particularly in the context of the use of high doses of rescue
b2-agonist such as salbutamol, as may be used during
episodes of sudden worsening, which are likely to have an
additive effect on prolongation of the QTc interval.24 The
relatively wide therapeutic margin observed for the effect
of indacaterol and a dose-related but modest effect at
several multiples of the likely therapeutic dose in patients
with asthma,21 together with the results of the present
study, provide reassurance at this stage of the drug’s
development that the effect of indacaterol would have no
greater significance than for any other LABA. However, since
patients with congenital ECG abnormalities are routinely
excluded from clinical studies such as this, the effect of b2-
adrenergic agonists on QTc interval deserves further careful
examination in view of the finding of an independent
association between asthma and an increased risk of cardiac
events in subjects with the long QTsyndrome,25 suggesting a
possible genetic linkage underlying the two diseases.
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a secondary objective. The FEV1 results from the current
study support the efficacy of indacaterol and are consistent
with the previous report of a 24-h duration of action in
patients with intermittent or persistent asthma, which also
demonstrated a rapid (o5min) onset of effect.10 In the
current study, pre-dose FEV1 values on Days 14 and 28 were
effectively trough values, which provide further supportive
evidence that indacaterol has 24-h bronchodilator effi-
cacy.10 The reductions in salbutamol use also support the
efficacy of indacaterol.
Another important aspect of the safety and tolerability of
long-acting b2-agonists in asthma is the question of
tolerance to the bronchodilator and bronchoprotective
effects, and to potential cross-tolerance to the bronchodi-
lating effect of ‘‘rescue’’ b2-agonists. Although these are
recognized phenomena,26,27 tolerance appears to be less of
a long-term clinical problem, at least in so far that
worsening symptoms and increasing use of rescue medica-
tion are not features of continuing use.28,29 Attenuation of
systemic b2-adrenoceptor mediated effects has also been
observed.30,31 Pharmacologically, indacaterol behaves as a
nearly full agonist at the b2-adrenoceptor in vitro,
5,32 and
this profile may lessen the risk of cross-tolerance to short-
acting b2-agonists. Additionally, a lack of tachyphylaxis to
the bronchoprotective effect of indacaterol against 5-HT
challenge was observed in a guinea pig model.5 In the
present study, there was no reduction in bronchodilator
efficacy over time with indacaterol: mean FEV1 increased
following the first dose, and the adjusted trough pre-dose
values remained at least 166mL higher than placebo at both
subsequent visits. However, since the pre-treatment b2-
agonist washout period was only 6 h (and therefore
insufficient to allow the receptors to recover to an
untreated state), no conclusions about tachyphylaxis can
be made.
The safety and efficacy results of the current study are
supported by those of a study with similar design, albeit in
patients with COPD. In this study, indacaterol demonstrated
good tolerability and overall safety profile at doses up to
800 mg.33
The pharmacokinetic analysis showed that indacaterol
exposure increased with increasing dose, but dose-propor-
tionality could not be concluded from this sparse data set.
Comparison of trough levels on Days 14 and 28 at the
different doses suggested a slight trend for accumulation.
In conclusion, the results of this study suggest that
indacaterol has a wide therapeutic index—it is well
tolerated, is neither associated with adverse cardiac effects
nor clinically significant changes in b2-mediated systemic
effects, and provides effective 24-h bronchodilation on
once-daily dosing. If these findings are substantiated in
large-scale, controlled clinical trials, indacaterol may
represent a significant improvement in selective b2-agonist
safety and efficacy.Acknowledgements
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